Section Arrow
IMVT.NASDAQ
- Immunovant
Quotes are at least 15-min delayed:2025/07/21 20:04 EDT
Regular Hours
Last
 17.7
-0.21 (-1.17%)
Day High 
18.32 
Prev. Close
17.91 
1-M High
19.0599 
Volume 
701.18K 
Bid
17.4
Ask
18.7
Day Low
17.48 
Open
18.02 
1-M Low
15.2601 
Market Cap 
3.06B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 17.63 
20-SMA 16.89 
50-SMA 15.77 
52-W High 34.47 
52-W Low 12.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.73/-3.15
Enterprise Value
3.06B
Balance Sheet
Book Value Per Share
4.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
NCNANuCana plc0.051+0.0033+6.92%-- 
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
Quotes are at least 15-min delayed:2025/07/21 20:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.